Researchers at the University of Oxford have made a significant stride in the fight against Parkinson's disease with early results from a pioneering trial of non-invasive ultrasound therapy. This breakthrough, detailed in a recent study published in Nature Communications, demonstrates for the first time that transcranial ultrasound stimulation (TUS) can effectively suppress pathological brain oscillations—a key biomarker of the condition—in patients. Conducted by teams from Oxford's Nuffield Department of Clinical Neurosciences, Nuffield Department of Surgical Sciences, and Institute of Biomedical Engineering, the proof-of-concept work opens doors to safer, surgery-free alternatives for managing Parkinson's symptoms.
Parkinson's disease affects over 10 million people worldwide, with around 145,000 diagnosed in the UK alone. Characterised by the progressive loss of dopamine-producing neurons in the substantia nigra, it leads to motor symptoms like tremors, bradykinesia (slowness of movement), rigidity, and postural instability. Non-motor issues such as cognitive decline, depression, and sleep disturbances further compound the burden. Current treatments primarily involve levodopa-based medications, which lose efficacy over time and cause dyskinesia (involuntary movements), or invasive deep brain stimulation (DBS), where electrodes are surgically implanted to deliver electrical pulses to the basal ganglia.
Deep Brain Stimulation: The Gold Standard and Its Limitations
Deep brain stimulation has transformed care for advanced Parkinson's patients since its approval in the late 1990s. By targeting structures like the subthalamic nucleus (STN) or globus pallidus interna (GPi), DBS disrupts excessive beta-band oscillations (13-30 Hz)—abnormal synchronised brain waves linked to motor impairment. Clinical trials show DBS reduces 'off' time by 50-70% and improves quality of life scores by up to 40%. However, it requires neurosurgery, carrying risks of infection (5%), haemorrhage (1-3%), and hardware complications, with costs exceeding £30,000 per patient plus lifelong maintenance.
Oxford's neuromodulation experts, including Professor Alexander Green and Professor James FitzGerald, have long pioneered DBS refinements. Their work at the John Radcliffe Hospital has optimised electrode placement using patient-specific imaging, achieving better outcomes. Yet, the invasiveness limits accessibility—only 1-2% of eligible UK patients receive it annually due to surgical risks and NHS waiting lists averaging 18 months.
Enter Transcranial Ultrasound Stimulation: A Non-Invasive Revolution
Transcranial ultrasound stimulation represents a paradigm shift. Unlike high-intensity focused ultrasound (HIFU) used for ablation (tissue destruction), low-intensity TUS modulates neural activity reversibly without heat damage. Sound waves (typically 0.5-1 MHz) penetrate the skull, converging at millimetre precision on deep targets. Oxford's innovation lies in custom acoustic lenses, computed via MRI-based skull models, to correct distortions and focus energy accurately.
The trial built on preclinical data showing TUS suppresses beta oscillations in rodent models of Parkinson's. Funded by the Rosetrees Trust, John Black Charitable Trust, and Medical Research Council, it leveraged Oxford's unique setup: four male patients (aged 55-68) already implanted with DBS sensing electrodes for real-time local field potential (LFP) recordings. This allowed direct validation of TUS effects without additional invasiveness.
The Oxford Trial Methodology: Precision Engineering Meets Neuroscience
In a randomised, sham-controlled crossover design, patients underwent TUS sessions targeting the globus pallidus—the basal ganglia hub implicated in bradykinesia. Pulses at 130 Hz mimicked DBS frequencies, delivered for 2 minutes via a wearable transducer array. Computational simulations predicted focal spots within 1 mm accuracy, verified post-hoc with post-stimulation imaging.
Brain activity was monitored via STN electrodes, focusing on beta power during 'off-medication' states to amplify pathological signals. Concurrently, surface EEG captured motor cortex changes, while a reaction-time task quantified bradykinesia. Sham conditions used mistimed pulses to blind participants. Safety endpoints included headache surveys and MRI checks—no adverse events occurred.
This interdisciplinary effort united Oxford Engineering Science's ultrasound expertise (led by Professor Robin Cleveland) with clinical neurologists, showcasing the university's strength in translational research.
Promising Early Results: Quantifiable Suppression of Beta Oscillations
The headline finding: TUS reduced ipsilateral STN beta power by a median 10.34% (95% CI: 3.81-16.87%, p<0.05, FDR-corrected)—a therapeutically relevant magnitude comparable to DBS acute effects (15-25% reductions). Effects propagated network-wide, correlating strongly with motor cortex desynchronisation (R²=0.98). Bradykinesia improved by 17.7% faster reaction times (95% CI: 8.95-26.41%, p<0.05), absent in sham.
No contralateral changes confirmed focality. Sustained effects lasted minutes post-stimulation, suggesting potential for repeated sessions. Lead author Dr John Eraifej noted, 'These results provide the first direct evidence that ultrasound can therapeutically modulate Parkinson's biomarkers non-invasively.'
Professor Green added, 'By replicating DBS benefits without surgery, TUS could expand access dramatically, especially in early-stage patients unsuitable for implants.'
Photo by Tetiana SHYSHKINA on Unsplash
Safety Profile and Patient Experience in the Trial
All participants tolerated TUS well, reporting mild scalp tingling akin to DBS trials. No lesions, seizures, or cognitive side effects emerged on follow-up MRIs and UPDRS assessments (Unified Parkinson's Disease Rating Scale). This aligns with over 100 prior TUS human studies showing skull transmission up to 80% without cavitation risks at low intensities (<720 mW/cm²).
Patients described sessions as 'effortless'—outpatient, 30-minute procedures under local anaesthesia. One participant shared anonymously: 'The reaction test felt quicker; it's empowering to see brain changes without scalp scars.'
Implications for Parkinson's Treatment and UK Healthcare
If scaled, TUS could alleviate DBS backlogs, treating 10,000+ UK patients yearly. Cost savings: £5,000-10,000 per procedure versus £30,000+ for DBS. For tremor-dominant cases, it complements medications; for advanced, enables bilateral targeting without cumulative surgical risks.
Beyond Parkinson's, Oxford plans TUS for essential tremor (affecting 700,000 UK adults), chronic pain (8 million sufferers), and depression. Integration with wearables could enable home use, revolutionising domiciliary care amid NHS pressures.Read the full Nature Communications study here.
Oxford's Leadership in Neuromodulation Research
The University of Oxford stands at the forefront of UK neuroscience, with NDCN ranking top globally for impact. The Oxford Parkinson's Disease Centre (OPDC) integrates genetics, imaging, and trials, discovering alpha-synuclein strains and GLP-1 agonists like exenatide (Phase 3 ongoing). IBME's ultrasound lab pioneers theranostics, from lithotripsy to drug delivery.
This trial exemplifies Oxford's 'bench-to-bedside' ethos, supported by £100m+ MRC/Wellcome funding. Collaborations with Imperial and UCL via UKRI hubs accelerate translation, positioning UK universities as neuromodulation hubs.
Challenges Ahead: From Proof-of-Concept to Clinic
Limitations include small sample (n=4), male-only cohort, and short-term effects. Larger trials (target n=50+) need sham optimisation and long-term efficacy data. Regulatory hurdles: MHRA Class III approval requires pivotal studies. Oxford's ongoing NCT06932185 (Phase 1/2, recruiting) addresses this, testing pallidal TUS standalone.View trial details on ClinicalTrials.gov.
- Scale custom lenses via 3D printing for mass production.
- Integrate AI targeting with fMRI for real-time adjustment.
- Combine with pharmacotherapy for synergistic effects.
Broader Impacts on Higher Education and Research Careers
Oxford's trial underscores UK higher education's role in health innovation, attracting £1.2bn R&D funding yearly. Biomedical engineering jobs surge 15%, with roles in ultrasound design, neural signal processing, and trial coordination booming. Universities like Oxford offer PhDs/MScs in neuromodulation, partnering with MedTech firms (e.g., Insightec).
For aspiring researchers, Oxford's DPhil programmes emphasise interdisciplinary skills—MATLAB modelling, MRI analysis, ethics. NHS-integrated trials foster clinician-scientist pathways, with salaries starting £40k rising to £100k+ for consultants.Explore related Oxford dementia ultrasound project.
Photo by Natalie Leung on Unsplash
Future Outlook: Towards Routine Non-Invasive Therapy
By 2030, TUS could enter Phase 3 trials, with NHS pilots. Oxford envisions 'ultrasound suites' akin to MRI centres. Patient advocacy groups like Parkinson's UK hail it as 'game-changing', potentially halving DBS reliance.
Stakeholders—NICE for appraisals, BRC for funding—must prioritise. For UK universities, it signals investment in ultrasound hubs, boosting exports (£5bn MedTech sector).
This Oxford trial not only promises relief for Parkinson's patients but elevates UK higher education as a beacon of innovative, patient-centred research.